12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AVP-923: Completed Phase II enrollment

Avanir completed enrollment in the double-blind, placebo-controlled, international Phase II PRIME trial evaluating 45/10, 30/10 and 20/10 mg AVP-923 twice daily for 12 weeks. In February, the company said it would reduce target enrollment in PRIME to 200 from 400 MS patients based on data from a Phase I trial of AVP-786, a deuterium-containing analog of dextromethorphan, plus low-dose quinidine to treat pain. The...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >